GlassScriptPhysician profile
Melissa D Bates
NPI 1962571331
$6,450.43
in general payments reported to CMS, 2019-2025
21 companies · $798 in 2025
The $798 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,239 · 2022: $1,348 · 2023: $855 · 2024: $2,210 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,548 · Travel and Lodging: $1,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.26 |
| Travel and Lodging | $1,315.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,682.30 | 2021-2025 | Interstim |
| Abbvie INC. | $2,181.37 | 2021-2025 | Vraylar |
| Astellas Pharma US INC | $538.97 | 2021-2025 | Veozah |
| Lilly USA, LLC | $416.62 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $135.28 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.70 | 2021-2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $55.87 | 2021-2022 | |
| Amgen INC. | $44.67 | 2021-2025 | Evenity |
| Inspire Medical Systems, INC. | $42.39 | 2023 | Inspire |
| Daiichi Sankyo INC. | $36.19 | 2022-2024 | Injectafer |
| Coloplast Corp | $30.92 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.57 | 2022 | |
| Urovant Sciences INC | $21.79 | 2022 | |
| Coopersurgical, INC. | $20.63 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $20.03 | 2024 | |
| Millicent US INC | $16.42 | 2021 | |
| Lundbeck LLC | $15.79 | 2022 | |
| Pfizer INC. | $13.91 | 2024 | |
| Exeltis, USA INC. | $12.86 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.